MGC Pharmaceuticals logo

MXC - MGC Pharmaceuticals Share Price

A$0.061 0.0  0.0%

Last Trade - 05/05/21

Small Cap
Market Cap £61.1m
Enterprise Value £61.4m
Revenue £588k
Position in Universe 843rd / 1907
Unlock MXC Revenue
Relative Strength (%)
1m -0.38%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -53.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.006 0.048 0.25 0.49 0.86 2.09 7.33 +223.6%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, MGCPharmaceuticals Ltd revenues decreased 58% to A$745K. Netloss before extraordinary items decreased 50% to A$5.9M.Revenues reflect Finance income decrease of 63% to A$3K.Lower net loss reflects Write-off/impairment expensedecrease from A$5M (expense) to A$0K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


MXC Revenue Unlock MXC Revenue

Net Income

MXC Net Income Unlock MXC Revenue

Normalised EPS

MXC Normalised EPS Unlock MXC Revenue

PE Ratio Range

MXC PE Ratio Range Unlock MXC Revenue

Dividend Yield Range

MXC Dividend Yield Range Unlock MXC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MXC EPS Forecasts Unlock MXC Revenue
Profile Summary

MGC Pharmaceuticals Limited is an Australia-based biopharma company. The Company is primarily focused on producing standardized, phytocannabinoid and plant-derived medicines. The Company’s Nature to Medicine strategy comprises the entire supply chain, from botanical research, to develop new strains of Cannabis Sativa, preclinical and clinical research, product manufacturing, distribution, as well as the development of drug delivery systems. The Group has also completed a Phase II double-blind, randomized, placebo controlled clinical trial in Israel and India, to evaluate the safety and efficacy of a natural anti-inflammatory based formulation ArtemiC on patients diagnosed with Corona Virus Disease 2019 (COVID-19).

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated October 21, 2005
Public Since December 21, 2006
No. of Shareholders: 9,470
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Exchange Australian Stock Exchange - SEATS
Shares in Issue 1,788,130,339
Free Float (0.0%)
Eligible for
MXC Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MXC
Upcoming Events for MXC
Frequently Asked Questions for MGC Pharmaceuticals
What is the MGC Pharmaceuticals share price?

As of 05/05/21, shares in MGC Pharmaceuticals are trading at A$0.061, giving the company a market capitalisation of £61.1m. This share price information is delayed by 15 minutes.

How has the MGC Pharmaceuticals share price performed this year?

Shares in MGC Pharmaceuticals are currently trading at A$0.061 and the price has moved by 0.126k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the MGC Pharmaceuticals price has moved by 68.09% over the past year.

What are the analyst and broker recommendations for MGC Pharmaceuticals?

Of the analysts with advisory recommendations for MGC Pharmaceuticals, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for MGC Pharmaceuticals is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will MGC Pharmaceuticals next release its financial results?

MGC Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the MGC Pharmaceuticals dividend yield?

MGC Pharmaceuticals does not currently pay a dividend.

Does MGC Pharmaceuticals pay a dividend?

MGC Pharmaceuticals does not currently pay a dividend.

When does MGC Pharmaceuticals next pay dividends?

MGC Pharmaceuticals does not currently pay a dividend.

How do I buy MGC Pharmaceuticals shares?

To buy shares in MGC Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of MGC Pharmaceuticals?

Shares in MGC Pharmaceuticals are currently trading at A$0.061, giving the company a market capitalisation of £61.1m.

Where are MGC Pharmaceuticals shares listed? Where are MGC Pharmaceuticals shares listed?

Here are the trading details for MGC Pharmaceuticals:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: MXC
What kind of share is MGC Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, MGC Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a MGC Pharmaceuticals share price forecast 2021?

Shares in MGC Pharmaceuticals are currently priced at A$0.061. At that level they are trading at 80.33% discount to the analyst consensus target price of 0.00.

Analysts covering MGC Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -0.004 for the next financial year.

How can I tell whether the MGC Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MGC Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 0.147k%. At the current price of A$0.061, shares in MGC Pharmaceuticals are trading at 60.65% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the MGC Pharmaceuticals PE Ratio?

We were not able to find PE ratio data for MGC Pharmaceuticals.

Who are the key directors of MGC Pharmaceuticals?

MGC Pharmaceuticals's management team is headed by:

Rachel Kerr - SEC
Brett Mitchell - CHM
Nativ Segev - EDR
Roby Zomer - CEO
Ross Grant Thomas Walker - NID
Stephen Parker - NED
Evan Hayes - NID
Sabina Suljakovic - OTH
Amir Polak - CTO
Nicole Godresse - OTH
Nadine Barry - SEC
Who are the major shareholders of MGC Pharmaceuticals?

Here are the top five shareholders of MGC Pharmaceuticals based on the size of their shareholding:

Segev (Nativ) Individual Investor
Percentage owned: 2.32% (53.0m shares)
Bishay (George) Individual Investor
Percentage owned: 1.61% (36.8m shares)
Zomer (Roby Reuven) Individual Investor
Percentage owned: 1.45% (33.0m shares)
Mitchell (Brett Anthony) Individual Investor
Percentage owned: 1.33% (30.4m shares)
CYT Investment Proprietary Limited Corporation
Percentage owned: 0.61% (14.0m shares)
Similar to MXC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.